JHVEPhoto The U.S. FDA has granted Inozyme Pharma ( NASDAQ: INZY ) Fast Track designation for NZ-701, its treatment of ABCC6 Deficiency.
The company noted it hopes to have an agreement with regulators on a pivotal trial design by the end of the year. In April, Inozyme released promising topline results from an ongoing phase 1/2 trial in adults showing clinical improvements were observed in vascular pathology, visual function, and patient reported outcomes. ABCC6 Deficiency is characterized by progressive calcification in the eyes, skin, and arteries.
More on Inozyme Pharma Seeking Alpha’s Quant Rating on Inozyme Pharma Historical earnings data for Inozyme Pharma Financial information for Inozyme Pharma.
